olaparib + durvalumab + durvalumab placebo + olaparib placebo + Carboplatin + Paclitaxel
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Endometrial Neoplasms
Conditions
Endometrial Neoplasms
Trial Timeline
May 5, 2020 → Apr 1, 2027
NCT ID
NCT04269200About olaparib + durvalumab + durvalumab placebo + olaparib placebo + Carboplatin + Paclitaxel
olaparib + durvalumab + durvalumab placebo + olaparib placebo + Carboplatin + Paclitaxel is a phase 3 stage product being developed by AstraZeneca for Endometrial Neoplasms. The current trial status is active. This product is registered under clinical trial identifier NCT04269200. Target conditions include Endometrial Neoplasms.
What happened to similar drugs?
0 of 20 similar drugs in Endometrial Neoplasms were approved
Approved (0) Terminated (0) Active (20)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04269200 | Phase 3 | Active |
Competing Products
20 competing products in Endometrial Neoplasms